Centro Hospitalar Universitário de São João, Porto, Portugal
Isabel Garrido, 1, Susana Lopes, MD, PhD1, Maria João Cardoso, 1, Angélica Ramos, 1, João Tiago Guimarães, 2, Guilherme Macedo, MD, PhD, FACG2 1Centro Hospitalar Universitário de São João, Porto, Porto, Portugal; 2Centro Hospitalar de São João, Porto, Porto, Portugal
Introduction: Inflammatory bowel disease (IBD) patients do not appear to be more susceptible to SARS-CoV-2 infection, including those on biologic treatment. Nonetheless, the rate of immunity to the coronavirus in these patients is currently unknown. This study was designed to assess the seroprevalence of COVID-19 in IBD patients undergoing biological treatment, including those who have already been vaccinated.
Methods: All adult patients with IBD undergoing biologic therapy in a major referral center were invited to perform a serological test (BioPlex 2200 SARS-CoV-2 IgG Panel, BIO-RAD, USA). On the day of the blood sample collection, they were asked to complete a questionnaire exploring a previous diagnosis of SARS-CoV-2 infection and vaccination.
Results: A total of 221 patients agreed to participate in the study, the majority females (55.2%), with a median age of 42 years old (IQR 32-54). IBD diagnosis included Crohn’s disease (76.8%) and ulcerative colitis (23.2%). The proportions of patients receiving anti-tumor necrosis factor (anti-TNF), vedolizumab and ustekinumab were 73.8%, 11.8% and 14.5%, respectively. Twenty-four patients (10.9%) had been diagnosed with COVID-19, with only 2 requiring hospitalization. Two thirds of these individuals had positive anti-SARS-CoV-2 IgG. Of the remaining 197 patients, 10 (5.1%) had antibodies compatible with a previous asymptomatic infection. This cohort also included 48 vaccinated patients (57.1% Pfizer-BioNTech, 14.3% Moderna, 28.6% AstraZeneca), 12 (25.0%) of whom had already received two doses. Full vaccination status was associated with a SARS-CoV-2 seroprevalence of 100%, while the seroprevalence of those who received one dose is 72.2%. There were no association between biologic therapies and positive SARS-CoV-2 serology (anti-TNF 86.2%, vedolizumab 72.7%, ustekinumab 62.5%; p=0.287). No patient was diagnosed with COVID-19 after vaccination.
Discussion: In this cohort, 5.1% of patients had asymptomatic SARS-CoV-2 infection, which supports the idea that immunosuppression is not an additional risk factor for the development of severe forms of COVID-19 in IBD. Vaccination against SARS-CoV-2 seems to be effective, even in these immunocompromised individuals.
Isabel Garrido indicated no relevant financial relationships.
Susana Lopes indicated no relevant financial relationships.
Maria João Cardoso indicated no relevant financial relationships.
Angélica Ramos indicated no relevant financial relationships.
João Tiago Guimarães indicated no relevant financial relationships.
Guilherme Macedo indicated no relevant financial relationships.
Isabel Garrido, 1, Susana Lopes, MD, PhD1, Maria João Cardoso, 1, Angélica Ramos, 1, João Tiago Guimarães, 2, Guilherme Macedo, MD, PhD, FACG2. P0579 - Seroprevalence of COVID-19 in Patients With Inflammatory Bowel Disease Under Biologic Treatment, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.